Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 3Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Thoracic 3

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

icotinib 2aflutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × EGF-R Positive Non-Small Cell Lung Cancer × Clear all
NCT06352502 2024-04-08

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Tang-Du Hospital

Unknown
30 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03749213 2018-11-21

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage â…¢A-N2 Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
36 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

NCT03349203 2018-07-18

Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
60 enrolled
Thoracic

EGF-R Positive Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡